Companies / BOC Sciences / Mupadolimab
BOC Sciences

Mupadolimab | BOC Sciences

Mupadolimab is a humanized anti-CD73 monoclonal antibody that inhibits production of immunosuppressive adenosine in the tumour microenvironment, binding to CD73 on B cells leads to their activation (including increased antibody production). Mupadolimab was developed for the treatment of head and neck cancer, and NSCLC.

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.